We are live on ! Find out more
MBRX icon

Moleculin Biotech
MBRX

11 hedge funds and large institutions have $2.04M invested in Moleculin Biotech in 2020 Q4 according to their latest regulatory filings, with 1 funds opening new positions, 2 increasing their positions, 2 reducing their positions, and 2 closing their positions.

New
Increased
Maintained
Reduced
Closed

0% more repeat investments, than reductions

Existing positions increased: 2 | Existing positions reduced: 2

0.78% less ownership

Funds ownership: 4.88% → 4.1% (-0.78%)

15% less funds holding

Funds holding: 13 → 11 (-2)

50% less first-time investments, than exits

New positions opened: 1 | Existing positions closed: 2

69% less capital inflows, than outflows

Capital inflows: $142K | Capital outflows: $456K

Holders
11
Holders Change
-2
Holders Change %
-15.38%
% of All Funds
0.19%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
1
Increased
2
Reduced
2
Closed
2
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
Geode Capital Management
Geode Capital Management
Massachusetts
+$71K
2
HighTower Advisors
HighTower Advisors
Illinois
+$35.5K
3
Renaissance Technologies
Renaissance Technologies
New York
+$35.5K

Top Sellers

Rank Fund Capital Flow
1
Qube Research & Technologies (QRT)
Qube Research & Technologies (QRT)
United Kingdom
-$177K
2
Millennium Management
Millennium Management
New York
-$171K
3
Wells Fargo
Wells Fargo
California
-$71K
4
Vanguard Group
Vanguard Group
Pennsylvania
-$35.5K
5
Pathstone Family Office
Pathstone Family Office
New Jersey
-$1K

MBRX Hedge Fund Activity: Q4 2020 in Review

11 of the 5,678 institutional investors tracked by Wall St. Rank reported a position in Moleculin Biotech (MBRX) for Q4 2020, worth a combined $2.04M — down 17% from $2.45M a quarter earlier.

Sellers outnumbered buyers: 2 funds closed out of MBRX and 1 opened new positions — a net loss of 1 holder — while 2 trimmed existing stakes and 2 added.

The largest buyer was Geode Capital Management, adding an estimated $71K. The largest seller was Qube Research & Technologies (QRT), cutting an estimated $177K.

  • 11 institutional investors held Moleculin Biotech (MBRX) as of Q4 2020, down from 13 in Q3 2020.
  • Funds reported $2.04M of Moleculin Biotech stock for Q4 2020, down 17% quarter-over-quarter.
  • 1 fund opened new Moleculin Biotech positions in Q4 2020 and 2 closed out, a net change of -1 holder.
  • The largest Moleculin Biotech buyer in Q4 2020 was Geode Capital Management, an estimated $71K added.
  • The largest Moleculin Biotech seller in Q4 2020 was Qube Research & Technologies (QRT), an estimated $177K sold.

Based on aggregated 13F filings for Q4 2020.